Zealand Pharma A/S
ZEAL
Rangering i aksjer
#5479
Zealand Pharma A/S is a Danish biotechnology firm dedicated to the... Zealand Pharma A/S is a Danish biotechnology firm dedicated to the identification, progression, and market introduction of peptide-based therapeutics. The company concentrates its efforts on treatments for gastrointestinal and metabolic ailments, as well as other specialized conditions where current medical options are insufficient. Its commercialized product, Dasiglucagon, is an injectable solution provided in a pre-filled syringe or autoinjector, used to address severe hypoglycemia. Furthermore, Zealand Pharma is actively developing Dasiglucagon for inclusion in bi-hormone artificial pancreas systems that integrate both insulin and dasiglucagon. The compound Dasiglucagon is also undergoing late-stage (Phase III) clinical trials for congenital hyperinsulinism. Another significant asset in its development pipeline is glepaglutide, a long-acting GLP-2 analog, which is likewise in Phase III clinical studies for treating short bowel syndrome. Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma A/S maintains strategic alliances with a range of partners, including Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc.
Aksjekurs
$35.23
Markedsverdi
$2.45B
Endring (1 dag)
-1.68%
Endring (1 år)
-50.79%
Land
DK
Handel Zealand Pharma A/S (ZEAL)
Kategori
Healthcare
Markedsverdi av Zealand Pharma A/S(ZEAL)
Markedsverdi: $2.45B
Per October 2026 har Zealand Pharma A/S en markedsverdi på $2.45B. Dette gjør Zealand Pharma A/S til det 5479th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Zealand Pharma A/S fra 2013 til 2026
ZEAL sammenlignet med topp 5 mest populære stocks
